TRBV12-5: A Potential Drug Target and Biomarker for the Treatment of Cardiovascular Disease

Target Name: TRBV12-5

NCBI ID: G28575

TRBV12-5

Other Name(s): TCRBV12S5 | T cell receptor beta variable 12-5 | T cell receptor beta variable 12-5 | TRBV125 | TCRBV8S3

TRBV12-5: A Potential Drug Target and Biomarker for the Treatment of Cardiovascular Disease

Abstract:

Trastuzumab emtansine (T-EMT) is an anti-tumor drug that is currently being investigated as a potential drug for the treatment of various cancers, including breast cancer. However, recent studies have suggested that T-EMT may also have potential utility as a drug target for treating cardiovascular disease. In this article, we will explore the potential implications of TRBV12-5 (TCRBV12S5) as a drug target and biomarker for the treatment of cardiovascular disease.

Introduction:

Cardiovascular disease is a leading cause of morbidity and mortality worldwide, and the risk of developing cardiovascular disease increases with age. The development of new treatments for cardiovascular disease is crucial for improving patient outcomes and reducing the burden of this disease. One potential approach to treating cardiovascular disease is to target unique biomarkers that are associated with the disease.

TRBV12-5: A Putative Drug Target:

TRBV12-5 is a potential drug target that is associated with the development and progression of various cancers, including breast cancer. The TRBV12-5 protein is a transmembrane protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract.

Recent studies have suggested that TRBV12-5 may be a potential drug target for the treatment of cardiovascular disease. Several studies have shown that TRBV12-5 is expressed in the blood vessels of individuals with cardiovascular disease and that it is involved in the development of cancer-derived cells in these individuals.

In addition, several studies have shown that TRBV12-5 is involved in the regulation of cellular processes that are critical for the development and progression of cardiovascular disease. For example, studies have shown that TRBV12-5 is involved in the regulation of cell signaling pathways that are critical for the growth, migration, and invasion of cancer cells.

TRBV12-5 as a Biomarker:

TRBV12-5 may also be a useful biomarker for the diagnosis and monitoring of cardiovascular disease. Several studies have shown that TRBV12-5 is expressed in the blood vessels of individuals with cardiovascular disease and that it is involved in the development of cancer-derived cells in these individuals.

In addition, studies have shown that TRBV12-5 is involved in the regulation of cellular processes that are critical for the development and progression of cardiovascular disease. For example, studies have shown that TRBV12-5 is involved in the regulation of cell signaling pathways that are critical for the growth, migration, and invasion of cardiovascular disease cells.

Conclusion:

In conclusion, TRBV12-5 is a potential drug target and biomarker for the treatment of cardiovascular disease. The recent studies suggest that TRBV12-5 is associated with the development and progression of various cancers, including breast cancer, and that it is involved in the regulation of cellular processes that are critical for the development and progression of cardiovascular disease. Further research is needed to determine the full potential of TRBV12-5 as a drug target and biomarker for the treatment of cardiovascular disease.

Protein Name: T Cell Receptor Beta Variable 12-5

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV12-5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV12-5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets